Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcadia Biosciences, Inc.RKDA · Entity 8593 | Director | August 19, 2024 | August 21, 2024 |
| LIFECORE BIOMEDICAL, INC. \DE\LNDC · Entity 6447 | Chief Executive Officer | May 23, 2022 | May 24, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcadia Biosciences, Inc.
Report date August 19, 2024 · Filed August 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.71 · Expires 2034-08-19 | Direct | 13,394 |
Reported balance
After 2024-08-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-19 · Grant · Acquired 10,909 · Balance 13,394 F1: The Option will become 100% vested and exercisable on the earlier to occur of (i) August 19, 2025 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The Option will become 100% vested and exercisable on the earlier to occur of (i) August 19, 2025 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service.
LIFECORE BIOMEDICAL, INC. \DE\
Report date May 23, 2022 · Filed May 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,883 |
Ending reported balance
After 2022-05-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-23 · Exercise / conversion · Acquired 55,000 · Balance 100,152 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Row 2 · 2022-05-23 · Tax withholding · Disposed 27,269 · Balance 72,883 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. |
| Common StockSEC Table II · derivative / convertible security · Expires 2022-05-23 | Direct | 0 |
Reported balance
After 2022-05-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-23 · Exercise / conversion · Disposed 55,000 · Balance 0 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2: The restricted stock units were granted on May 23, 2019. F3: The restricted stock units vested on May 23, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.
F2: The restricted stock units were granted on May 23, 2019.
F3: The restricted stock units vested on May 23, 2022.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SunOpta Inc.
Report date May 01, 2026 · Filed May 04, 2026
Section 16 reporting ended · disclosed 2026-05-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-01 transaction · row 1
1 source rowRow 1 · 2026-05-01 · Disposition to issuer · Disposed 233,283 · Balance 0 F1: Pursuant to the Arrangement Agreement (the "Arrangement Agreement"), dated as of February 6, 2026, by and among SunOpta Inc. ("SunOpta"), Pegasus BidCo B.V. ("Parent") and 2786694 Alberta Ltd. ("Purchaser"), Purchaser acquired all of SunOpta's issued and outstanding common shares in the capital of SunOpta (the "Common Shares") by way of a court-approved statutory plan of arrangement under Section 192 of the Canada Business Corporations Act (the "Arrangement"). At the effective time of the Arrangement (the "Effective Time"), each of SunOpta's issued and outstanding Common Shares were transferred to Purchaser for consideration of $6.50 per share in cash, less applicable withholdings (the "Consideration"). |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-01 · Disposition to issuer · Disposed 20,193 · Balance 0 F2: Each Restricted Stock Unit represents a contingent right to receive one share of STKL common stock. F3: At the Effective Time, each restricted stock unit ("RSU") held by the reporting person was surrendered in exchange for, subject to any withholding, a cash payment equal to the Consideration in respect of each Common Share underlying such RSU. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Arrangement Agreement (the "Arrangement Agreement"), dated as of February 6, 2026, by and among SunOpta Inc. ("SunOpta"), Pegasus BidCo B.V. ("Parent") and 2786694 Alberta Ltd. ("Purchaser"), Purchaser acquired all of SunOpta's issued and outstanding common shares in the capital of SunOpta (the "Common Shares") by way of a court-approved statutory plan of arrangement under Section 192 of the Canada Business Corporations Act (the "Arrangement"). At the effective time of the Arrangement (the "Effective Time"), each of SunOpta's issued and outstanding Common Shares were transferred to Purchaser for consideration of $6.50 per share in cash, less applicable withholdings (the "Consideration").
F2: Each Restricted Stock Unit represents a contingent right to receive one share of STKL common stock.
F3: At the Effective Time, each restricted stock unit ("RSU") held by the reporting person was surrendered in exchange for, subject to any withholding, a cash payment equal to the Consideration in respect of each Common Share underlying such RSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2021 Filed Jan 19, 2021 22:48 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | PurchaseCommon Stock | 10,000 | $10.98 | $109,800.00 |
DisclosureSEC source: 0001593968-21-000152 · primary_01.xml · nonDerivative · entry 1 Bolles Albert D. · CIK 0001603163 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,152 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $10.80 to $11.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| October 23, 2020 Filed Oct 26, 2020 19:47 UTC | SunOpta Inc. STKL · Entity 49798 | GrantCommon Shares | 1,975 | $7.34 | $14,496.50 |
DisclosureSEC source: 0001209191-20-055795 · doc4.xml · nonDerivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,424 F1 · kind: The shares were issued in lieu of cash to the reporting person for service on the board of directors. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 16:28 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantPerformance-Based Restricted Stock Units · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-014172 · wf-form4_160165612202773.xml · derivative · entry 1 Bolles Albert D. · CIK 0001603163 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2024-09-30 F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones. F3 · derivative.exercise_date: The performance-based restricted stock units vest, if at all, based on the Issuer's achievement of certain stock price milestones. F2 · derivative.underlying_shares: Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones. F2 · balance_after: Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 22:44 UTC | SunOpta Inc. STKL · Entity 49798 | GrantCommon Shares | 3,098 | $4.68 | $14,498.64 |
DisclosureSEC source: 0001209191-20-044839 · doc4.xml · nonDerivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,449 F1 · kind: The shares were issued in lieu of cash to the reporting person for service on the board of directors. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 22:16 UTC | SunOpta Inc. STKL · Entity 49798 | GrantRestricted Stock Units · Derivative | 19,547 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-038773 · doc4.xml · derivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,547 Underlying: Common Shares · 19,547 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of STKL common stock. F2 · derivative.expiration_date: The Restricted Stock Units do not have an expiration date. Read SEC document |
| June 14, 2020 Filed Jun 17, 2020 00:36 UTC | SunOpta Inc. STKL · Entity 49798 | Exercise / conversionRestricted Stock Units · Derivative | 24,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037141 · doc4.xml · derivative · entry 2 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 24,194 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of STKL common stock. F2 · derivative.expiration_date: The Restricted Stock Units do not have an expiration date. Read SEC document |
| June 14, 2020 Filed Jun 17, 2020 00:36 UTC | SunOpta Inc. STKL · Entity 49798 | Exercise / conversionCommon Shares | 24,194 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-037141 · doc4.xml · nonDerivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of STKL common stock. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 15:10 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 9,137 | $0.00 Strike: $3.69 | $0.00 |
DisclosureSEC source: 0001209191-20-033825 · doc4.xml · derivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,463 Underlying: Common Stock · 9,137 shares Expires 2030-06-01 F1 · derivative.exercise_date: The Option will become 100% vested and exercisable on the earlier to occur of (i) June 1, 2021 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service. Read SEC document |
| May 27, 2020 Filed May 29, 2020 19:36 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantIncentive Stock Option (Right to Buy) · Derivative | 8,928 | $11.20 Strike: $11.20 | $99,993.60 |
DisclosureSEC source: 0001628280-20-008614 · wf-form4_159078094521279.xml · derivative · entry 2 Bolles Albert D. · CIK 0001603163 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 8,928 shares Expires 2027-05-27 Read SEC document |
| May 27, 2020 Filed May 29, 2020 19:36 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 91,072 | $11.20 Strike: $11.20 | $1,020,006.40 |
DisclosureSEC source: 0001628280-20-008614 · wf-form4_159078094521279.xml · derivative · entry 1 Bolles Albert D. · CIK 0001603163 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,072 Underlying: Common Stock · 91,072 shares Expires 2027-05-27 Read SEC document |
| November 06, 2019 Filed Nov 7, 2019 00:52 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | PurchaseCommon Stock | 850 | $10.91 | $9,273.50 |
DisclosureSEC source: 0001628280-19-013564 · wf-form4_157308792580047.xml · nonDerivative · entry 2 Bolles Albert D. · CIK 0001603163 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,152 F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $10.90 to $10.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 00:52 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | PurchaseCommon Stock | 3,800 | $10.69 | $40,622.00 |
DisclosureSEC source: 0001628280-19-013564 · wf-form4_157308792580047.xml · nonDerivative · entry 1 Bolles Albert D. · CIK 0001603163 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,302 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $10.40 to $10.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 20:51 UTC | SunOpta Inc. STKL · Entity 49798 | GrantRestricted Stock Units · Derivative | 24,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037730 · doc4.xml · derivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,194 Underlying: Common Shares · 24,194 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of STKL common stock. F2 · derivative.expiration_date: The Restricted Stock Units do not have an expiration date. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 23:39 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 6,912 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-19-034580 · doc4.xml · derivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,326 Underlying: Common Stock · 6,912 shares Expires 2029-06-03 F1 · derivative.exercise_date: The Option will become 100% vested and exercisable on the earlier to occur of (i) June 3, 2020 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service. Read SEC document |
| May 30, 2019 Filed May 31, 2019 00:36 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRestricted Stock Unit · Derivative | 4,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-007408 · wf-form4_155926297950898.xml · derivative · entry 2 Bolles Albert D. · CIK 0001603163 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,240 shares Expires 2019-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on May 30, 2018. F3 · derivative.exercise_date: The restricted stock units vested on May 30, 2019. Read SEC document |
| May 30, 2019 Filed May 31, 2019 00:36 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionCommon Stock | 4,240 | $9.91 | $42,018.40 |
DisclosureSEC source: 0001628280-19-007408 · wf-form4_155926297950898.xml · nonDerivative · entry 1 Bolles Albert D. · CIK 0001603163 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document |
| May 24, 2019 Filed May 29, 2019 23:20 UTC | SunOpta Inc. STKL · Entity 49798 | Exercise / conversionRestricted Stock Units · Derivative | 11,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033311 · doc4.xml · derivative · entry 2 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 11,688 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of STKL common stock. F2 · derivative.expiration_date: The Restricted Stock Units do not have an expiration date. Read SEC document |
| May 24, 2019 Filed May 29, 2019 23:20 UTC | SunOpta Inc. STKL · Entity 49798 | Exercise / conversionCommon Shares | 11,688 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-033311 · doc4.xml · nonDerivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of STKL common stock. Read SEC document |
| May 23, 2019 Filed May 29, 2019 01:15 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantIncentive Stock Option (Right to Buy) · Derivative | 32,085 | $9.35 Strike: $9.35 | $299,994.75 |
DisclosureSEC source: 0001628280-19-007277 · wf-form4_155909250152442.xml · derivative · entry 3 Bolles Albert D. · CIK 0001603163 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,000 Underlying: Common Stock · 32,085 shares Expires 2026-05-23 Read SEC document |
| May 23, 2019 Filed May 29, 2019 01:15 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 129,915 | $9.35 Strike: $9.35 | $1,214,705.25 |
DisclosureSEC source: 0001628280-19-007277 · wf-form4_155909250152442.xml · derivative · entry 2 Bolles Albert D. · CIK 0001603163 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,915 Underlying: Common Stock · 129,915 shares Expires 2026-05-23 Read SEC document |
| May 23, 2019 Filed May 29, 2019 01:15 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantRight to Buy Restricted Stock Units (RSU) · Derivative | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-007277 · wf-form4_155909250152442.xml · derivative · entry 1 Bolles Albert D. · CIK 0001603163 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2022-05-23 F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.exercise_date: Restricted Stock Units will vest on the 3rd anniversary of the grant date and will be automatically settled in shares of common stock subject to vesting at a rate of 1 share per unit. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 23:27 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 3,204 | $0.00 Strike: $10.80 | $0.00 |
DisclosureSEC source: 0001209191-18-036791 · doc4.xml · derivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,414 Underlying: Common Stock · 3,204 shares Expires 2028-06-06 F1 · derivative.exercise_date: The Option will become 100% vested and excercisable on the earlier to occur of (i) June 6, 2019 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:37 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRight to Buy Restricted Stock Unit (RSU) · Derivative | 4,240 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-18-011103 · rdgdoc.xml · derivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,240 Underlying: Common Stock · 4,240 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
| May 24, 2018 Filed May 29, 2018 22:58 UTC | SunOpta Inc. STKL · Entity 49798 | Exercise / conversionRestricted Stock Units · Derivative | 9,474 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033976 · doc4.xml · derivative · entry 2 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 9,474 shares Expires 2018-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of STKL common stock. Read SEC document |
| May 24, 2018 Filed May 29, 2018 22:58 UTC | SunOpta Inc. STKL · Entity 49798 | Exercise / conversionCommon Shares | 9,474 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-033976 · doc4.xml · nonDerivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of STKL common stock. Read SEC document |
| May 24, 2018 Filed Jul 16, 2018 21:44 UTC | SunOpta Inc. STKL · Entity 49798 | GrantRestricted Stock Units · Derivative | 11,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-042694 · doc4.xml · derivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,688 Underlying: common shares · 11,688 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of STKL common stock. F2 · date: Due to an administrative oversight, the filing was not immediately completed after the date of grant. F3 · derivative.expiration_date: The Restricted Stock Units do not have an expiration date. Read SEC document |
| May 23, 2018 Filed May 25, 2018 21:41 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRestricted Stock Unit · Derivative | 4,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-010776 · rdgdoc.xml · derivative · entry 2 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,286 shares Expires 2018-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on June 1, 2017. F3 · derivative.exercise_date: The restricted stock units vested on May 23, 2018. Read SEC document |
| May 23, 2018 Filed May 25, 2018 21:41 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionCommon Stock | 4,286 | $13.65 | $58,503.90 |
DisclosureSEC source: 0001437749-18-010776 · rdgdoc.xml · nonDerivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document |
| May 12, 2018 Filed May 16, 2018 00:37 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 8,210 | $0.00 Strike: $9.16 | $0.00 |
DisclosureSEC source: 0001209191-18-030360 · doc4.xml · derivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,210 Underlying: Common Stock · 8,210 shares Expires 2028-05-12 F1 · derivative.exercise_date: The shares subject to the Option shall vest and become exercisable in three (3) equal annual installments, with one-third of the shares subject to the Option vesting on each of the first three (3) anniversaries of the date of the award, subject to the Participant's continued service through each applicable vesting date. Read SEC document |
| November 08, 2017 Filed Nov 10, 2017 00:24 UTC | SunOpta Inc. STKL · Entity 49798 | Exercise / conversionRestricted Stock Units · Derivative | 7,995 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-060092 · doc4.xml · derivative · entry 2 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 7,995 shares Expires 2017-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of STKL common stock. Read SEC document |
| November 08, 2017 Filed Nov 10, 2017 00:24 UTC | SunOpta Inc. STKL · Entity 49798 | Exercise / conversionCommon Shares | 7,995 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-060092 · doc4.xml · nonDerivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of STKL common stock. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 23:15 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRight to Buy Restricted Stock Unit (RSU) · Derivative | 4,286 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-17-010663 · rdgdoc.xml · derivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,286 Underlying: Common Stock · 4,286 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
| May 25, 2017 Filed May 26, 2017 22:54 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRestricted Stock Unit · Derivative | 5,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-010189 · rdgdoc.xml · derivative · entry 2 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,282 shares Expires 2017-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on May 25, 2016. F3 · derivative.exercise_date: The restricted stock units vested on May 25, 2017. F3 · derivative.expiration_date: The restricted stock units vested on May 25, 2017. Read SEC document |
| May 25, 2017 Filed May 26, 2017 22:54 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionCommon Stock | 5,282 | $13.50 | $71,307.00 |
DisclosureSEC source: 0001437749-17-010189 · rdgdoc.xml · nonDerivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document |
| May 24, 2017 Filed May 26, 2017 19:48 UTC | SunOpta Inc. STKL · Entity 49798 | GrantRestricted Stock Units · Derivative | 9,474 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-035786 · doc4.xml · derivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,474 Underlying: common shares · 9,474 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of STKL common stock. F2 · derivative.expiration_date: The Restricted Stock Units do not have an expiration date. Read SEC document |
| May 12, 2017 Filed May 15, 2017 19:59 UTC | SunOpta Inc. STKL · Entity 49798 | PurchaseCommon Shares | 20,000 | $8.00 | $160,000.00 |
DisclosureSEC source: 0001209191-17-032318 · doc4.xml · nonDerivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Read SEC document |
| December 01, 2016 Filed Dec 1, 2016 22:24 UTC | SunOpta Inc. STKL · Entity 49798 | Purchasecommon shares | 40,000 | $7.35 | $293,956.00 |
DisclosureSEC source: 0001209191-16-152697 · doc4.xml · nonDerivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.30 to $7.40, inclusive. The reporting person undertakes to provide to SunOpta, Inc., any security holder of SunOpta, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| November 08, 2016 Filed Nov 10, 2016 22:48 UTC | SunOpta Inc. STKL · Entity 49798 | GrantRestricted Stock Units · Derivative | 7,995 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-149437 · doc4.xml · derivative · entry 2 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,317 Underlying: common shares · 7,995 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of STKL common stock. F2 · derivative.expiration_date: The Restricted Stock Units do not have an expiration date. Read SEC document |
| November 08, 2016 Filed Nov 10, 2016 22:48 UTC | SunOpta Inc. STKL · Entity 49798 | GrantStock Option (right to buy) · Derivative | 5,322 | $0.00 Strike: $6.65 | $0.00 |
DisclosureSEC source: 0001209191-16-149437 · doc4.xml · derivative · entry 1 Bolles Albert D. · CIK 0001603163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,322 Underlying: common shares · 5,322 shares Expires 2026-11-08 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.